Cipla to acquire 33 per cent stake in Clean Max Auriga Power
The company will invest up Rs six crores for the 33 per cent stake in the target firm.
December 17, 2021
by expresspharma
Cipla Q1 net profit rises 25 per cent to Rs 709.92 crores
The company had posted a net profit of Rs 566.04 crores in the corresponding period of the previous fiscal, Cipla said in a filing to BSE.
August 9, 2021
by expresspharma
Cipla gets permission from DCGI to import Moderna’s COVID-19 vaccine
The company has to submit seven days safety assessment of the vaccine in the first 100 beneficiaries before rolling out the vaccine for further immunisation programme.
June 30, 2021
by expresspharma
Cipla, Dr Reddy’s, Emcure, Sun Pharma and Torrent to partner for clinical trial of Molnupiravir
As per the directive of the SEC of the CDSCO, Dr Reddy’s will conduct the clinical trial and the other four pharma companies will be required to demonstrate equivalence of their product to the product used by Dr Reddy’s in its clinical trial.
June 30, 2021
by expresspharma
Cipla gets USFDA nod for inhalation product
The approved product is a generic version of Sunovion Pharmaceuticals Inc's Brovana.
June 25, 2021
by expresspharma
Cipla seeks clarity, guidance from Govt for import of COVID-19 vaccine
The company is seeking fast-track approvals to expeditiously bring Moderna's single-dose COVID-19 booster vaccine into India.
June 3, 2021
by expresspharma
ipla seeks clarity, guidance from Govt for import of COVID-19 vaccine
The company is seeking fast-track approvals to expeditiously bring Moderna's single-dose COVID-19 booster vaccine into India.
June 2, 2021
by expresspharma
India might get Moderna’s single-dose COVID-19 vaccine next year; Pfizer offers five crore shots in 2021
While Moderna has conveyed to Indian authorities that it does not have surplus vaccines to share in 2021, there are limited prospects of Johnson & Johnson exporting its jabs from the US to other countries in the near future.
May 27, 2021
by expresspharma
Cipla to market Roche’s antibody cocktail pan-India, first batch currently available
Casirivimab and Imdevimab is indicated for restricted use in emergency situation for the treatment of mild to moderate COVID-19 in patients who are at high risk of severe COVID-19.
May 25, 2021
by expresspharma
Cipla launches ViraGen, a COVID-19 RT-PCR test
Cipla announced the commercialisation of a polymerase chain reaction (RT-PCR) test kit ‘ViraGen’ for COVID-19 in India, in partnership with Ubio Biotechnology Systems. ViraGen is Cipla’s third offering in the COVID-19 testing segment.
May 21, 2021
by expresspharma
Lilly signs licensing agreements with Cipla, Lupin and Sun Pharma for Baricitinib in India
Eli Lilly and Company announced that it has issued royalty-free, non-exclusive voluntary licenses to established Indian pharmaceutical manufacturers of generic medicines, Cipla, Lupin and Sun Pharmaceutical Industries, who are collaborating with Lilly ...
May 11, 2021
by expresspharma
Cipla signs licensing deal with Lilly to manufacture and commercialise baricitinib in India
Baricitinib was issued a restricted emergency use approval by CDSCO to treat COVID-19.
May 10, 2021
by expresspharma